Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SAN DIEGO, March 09, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 16, 2017 at 5:00 p.m. ET to report its fourth quarter and full year 2016 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 85799370. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
